Editorial: Cellular mutation
By Sacramento Bee,
Sacramento Bee
| 06. 02. 2006
In her latest effort to reform California's $3 billion stem cell research institute, state Sen. Deborah Ortiz, D-Sacramento, has introduced SB 401, a proposed ballot measure that seeks to close gaps in Proposition 71, the 2004 initiative that created the stem cell agency.
By our measure, Ortiz's bill doesn't go far enough. It doesn't require scientists reviewing multimillion-dollar grants to disclose publicly any interest in companies that could benefit from those grants. Such a requirement should be the bottom line for any changes in Proposition 71.
Fortunately, there is time to improve this legislation before it comes before the Assembly. The bill, however, has had one positive effect: It has prompted Robert Klein II, the institute's chairman and Proposition 71's author, to concede that initiatives are a poor way to make policy.
Klein made the comment on an early version of Ortiz's bill: "This is legislation that creates an initiative. So if this is passed, you can't even, if there's an error in it, you couldn't even change it with legislation. You have to go back to the voters with...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...